$ALGS
Aligos Therapeutics, Inc.

2020 Q4 Form 10-Q Financial Statement

#000119312520303749 Filed on November 25, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.210M $4.230M
YoY Change
% of Gross Profit
Research & Development $28.08M $17.33M $11.73M
YoY Change 47.77%
% of Gross Profit
Depreciation & Amortization $730.0K $708.0K $387.0K
YoY Change -42.52% 82.95%
% of Gross Profit
Operating Expenses $34.29M $21.56M $14.50M
YoY Change 48.63%
Operating Profit -$21.56M -$14.50M
YoY Change 48.63%
Interest Expense $270.0K $230.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$190.0K -$11.97M
YoY Change
Pretax Income -$34.20M -$33.30M -$14.05M
YoY Change 136.97%
Income Tax $220.0K $0.00
% Of Pretax Income
Net Earnings -$34.42M -$33.30M -$14.05M
YoY Change 136.97%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$962.8K -$902.7K
COMMON SHARES
Basic Shares Outstanding 38.12M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $243.5M $70.10M
YoY Change
Cash & Equivalents $220.4M $31.82M $21.13M
Short-Term Investments $23.10M $38.20M
Other Short-Term Assets $5.944M $3.073M
YoY Change 193.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $250.0M $73.69M
YoY Change 107.96%
LONG-TERM ASSETS
Property, Plant & Equipment $8.007M $8.592M
YoY Change -5.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change
Other Assets $377.0K $2.844M
YoY Change 100.53%
Total Long-Term Assets $15.29M $18.49M
YoY Change -41.87%
TOTAL ASSETS
Total Short-Term Assets $250.0M $73.69M
Total Long-Term Assets $15.29M $18.49M
Total Assets $265.3M $92.18M
YoY Change 81.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.313M $7.682M
YoY Change -12.05%
Accrued Expenses $16.56M $9.782M
YoY Change 117.98%
Deferred Revenue $7.891M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $100.0K
YoY Change
Total Short-Term Liabilities $30.27M $19.98M
YoY Change 119.09%
LONG-TERM LIABILITIES
Long-Term Debt $500.0K $14.70M
YoY Change
Other Long-Term Liabilities $379.0K $295.0K
YoY Change
Total Long-Term Liabilities $379.0K $295.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $30.27M $19.98M
Total Long-Term Liabilities $379.0K $295.0K
Total Liabilities $45.26M $46.29M
YoY Change 54.31%
SHAREHOLDERS EQUITY
Retained Earnings -$174.7M -$140.3M
YoY Change 163.91%
Common Stock $395.0M $3.620M
YoY Change 27695.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $220.0M -$136.7M -$47.02M
YoY Change
Total Liabilities & Shareholders Equity $265.3M $92.18M
YoY Change 81.07%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$34.42M -$33.30M -$14.05M
YoY Change 136.97%
Depreciation, Depletion And Amortization $730.0K $708.0K $387.0K
YoY Change -42.52% 82.95%
Cash From Operating Activities -$19.68M -$16.57M
YoY Change -30.78%
INVESTING ACTIVITIES
Capital Expenditures -$60.00K -$340.0K
YoY Change -95.59%
Acquisitions
YoY Change
Other Investing Activities $15.00M $27.00M
YoY Change -210.78%
Cash From Investing Activities $14.94M $26.66M
YoY Change -200.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 193.3M -950.0K
YoY Change 125.97%
NET CHANGE
Cash From Operating Activities -19.68M -16.57M
Cash From Investing Activities 14.94M 26.66M
Cash From Financing Activities 193.3M -950.0K
Net Change In Cash 188.6M 9.140M
YoY Change 346.66%
FREE CASH FLOW
Cash From Operating Activities -$19.68M -$16.57M
Capital Expenditures -$60.00K -$340.0K
Free Cash Flow -$19.62M -$16.23M
YoY Change -27.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31816000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69565000
CY2020Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
556000
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
538000
CY2020Q3 algs Fair Value Of Investments In Available For Sale Securities
FairValueOfInvestmentsInAvailableForSaleSecurities
23241000
CY2020Q3 algs Investments In Held To Maturity Securities
InvestmentsInHeldToMaturitySecurities
15007000
CY2019Q4 algs Investments In Held To Maturity Securities
InvestmentsInHeldToMaturitySecurities
48098000
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
3073000
CY2020Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P4Y
CY2020Q3 us-gaap Lessee Finance Lease Remaining Lease Term
LesseeFinanceLeaseRemainingLeaseTerm
P8Y
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2025000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
73693000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
120226000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7054000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7570000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8592000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8517000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2844000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
188000
CY2020Q3 algs Long Term Investments In Held To Maturity Securities
LongTermInvestmentsInHeldToMaturitySecurities
0
CY2019Q4 algs Long Term Investments In Held To Maturity Securities
LongTermInvestmentsInHeldToMaturitySecurities
10019000
CY2020Q3 us-gaap Assets
Assets
92183000
CY2019Q4 us-gaap Assets
Assets
146520000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7682000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3767000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9782000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7599000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2444000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-33297000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-14051000
us-gaap Net Income Loss
NetIncomeLoss
-74123000
us-gaap Net Income Loss
NetIncomeLoss
-34080000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3027825
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2084719
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2378000
CY2020Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
76000
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
74000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
19984000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13818000
CY2020Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
620000
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
461000
CY2020Q3 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
14560000
CY2019Q4 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
3174000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10696000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11701000
CY2020Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
130000
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
178000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
295000
CY2020Q3 us-gaap Liabilities
Liabilities
46285000
CY2019Q4 us-gaap Liabilities
Liabilities
29332000
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2829160
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1851811
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-11.00
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.74
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-26.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-18.40
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3620000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1421000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-140320000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66197000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
32000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-115000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-136668000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-64891000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92183000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146520000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
0
dei Document Type
DocumentType
10-Q
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25953481
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12900764
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25953481
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12900764
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17332000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11729000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51809000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29065000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4225000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2775000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11739000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6542000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
21557000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
14504000
us-gaap Operating Expenses
OperatingExpenses
63548000
us-gaap Operating Expenses
OperatingExpenses
35607000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21557000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14504000
us-gaap Operating Income Loss
OperatingIncomeLoss
-63548000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35607000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-33297000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14051000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-74181000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
563000
algs Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
0
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-34080000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-58000
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Trading Symbol
TradingSymbol
ALGS
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address Address Line1
EntityAddressAddressLine1
One Corporate Drive, 2nd Floor
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
466-6059
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Central Index Key
EntityCentralIndexKey
0001799448
dei Security12b Title
Security12bTitle
Common Stock, par value, $0.0001 per share
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38117910
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-104573000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
148000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1016000
CY2020Q3 algs Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
156000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
243000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1674000
algs Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
282000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-33372000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
151000
CY2019Q3 algs Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
224000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-13749000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
604000
algs Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
224000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
70000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
70000
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="text-align:left;;vertical-align:top;;width:4%;"><div style="font-weight:bold;display:inline;">1.</div></td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Organization </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Description of <div style="letter-spacing: 0px; top: 0px;;display:inline;">b</div>usiness </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Aligos Therapeutics, Inc. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;Aligos-US&#8221;)</div> was incorporated in the state of Delaware on February&#160;5, 2018 (&#8220;inception&#8221;). On September&#160;10, 2018, the Company formed Aligos Belgium BVBA (&#8220;Aligos-Belgium&#8221;), a limited liability company organized under the laws of Belgium. On March&#160;30, 2020, the Company formed as a wholly owned subsidiary, Aligos Australia Pty LTD (&#8220;Aligos-Australia&#8221;), a proprietary limited company, and together with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Aligos-US</div> and Aligos-Belgium being the &#8220;Company&#8221; or &#8220;Aligos&#8221;. </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Aligos is a clinical-stage biopharmaceutical company developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses therapeutics for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-alcoholic</div> steatohepatitis (&#8220;NASH&#8221;). </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is devoting substantially all of its efforts to the research and development of its drug candidates. The Company has not generated any product revenue to date. The Company is also subject to a number of risks similar to other companies in the biotechnology industry, including the uncertainty of success of its nonclinical studies and clinical trials, regulatory approval of drug candidates, uncertainty of market acceptance of products, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, dependence on third-parties, product liability, and dependence on key individuals. </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Reverse stock split </div></div></div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;8, 2020, the Company&#8217;s board of directors approved a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-9.3197</div></div> reverse stock split (the &#8220;Reverse Stock Split&#8221;) of the Company&#8217;s common stock and redeemable convertible preferred stock to be consummated prior to the effectiveness of the Company&#8217;s planned initial public offering (&#8220;IPO&#8221;). The par value and authorized shares of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented. The Company filed an amended and restated certificate of incorporation in Delaware on October&#160;9, 2020 that automatically effectuated the Reverse Stock Split without any further action required. </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Initial public offering </div></div></div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;20, 2020, the Company closed its IPO and issued 10,000,000 shares of its common stock at a public offering price of $15.00 per share for net proceeds of $135,400, after deducting underwriting discounts and commissions of $10,500 and estimated expenses of $4,100. In connection with the IPO, all shares of Series A redeemable convertible preferred stock (&#8220;Series A&#8221;), Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> redeemable convertible preferred stock (&#8220;Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1&#8221;)</div> and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> redeemable convertible preferred stock (&#8220;Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2&#8221;)</div> converted into 19,761,870 shares of voting common stock and 3,092,338 shares of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> common stock. On November&#160;5, 2020, the underwriters of the IPO partially exercised their overallotment option by purchasing an additional 1,150,000 shares from the Company, resulting in an additional $16,043 in net proceeds, after deducting underwriting discounts and commissions of $1,208. </div></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-181000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
786000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
437000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
787000
us-gaap Depreciation
Depreciation
2005000
us-gaap Depreciation
Depreciation
868000
us-gaap Share Based Compensation
ShareBasedCompensation
1674000
us-gaap Share Based Compensation
ShareBasedCompensation
604000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-296000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
294000
algs Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-95000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21667000
us-gaap Minority Interest Change In Redemption Value
MinorityInterestChangeInRedemptionValue
-11387000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1049000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3677000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-248000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-37731000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2880000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
268000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70103000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24547000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32372000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1875000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1639000
algs Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-939000
algs Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
229000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54579000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31749000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
22000000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
45279000
us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
43100000
us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
76000000
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
0
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
45334000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2003000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2065000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17818000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28601000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
350000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
405000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
46000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
27000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
197000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
295000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-970000
us-gaap Interest Paid
InterestPaid
4000
us-gaap Interest Paid
InterestPaid
3000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
algs Leasehold Improvement Directly Paid By The Landlord
LeaseholdImprovementDirectlyPaidByTheLandlord
79000
algs Leasehold Improvement Directly Paid By The Landlord
LeaseholdImprovementDirectlyPaidByTheLandlord
3990000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
198000
algs Market To Market Adjustment For Available For Sale Investments
MarketToMarketAdjustmentForAvailableForSaleInvestments
132000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
252000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
137000
algs Vesting Of Early Exercised Options Value
VestingOfEarlyExercisedOptionsValue
283000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
213000
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of estimates </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets and liabilities, and disclosures of contingent assets and liabilities at the dates of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Areas where management uses subjective judgments include, but are not limited to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, lease obligations, impairment of long-lived assets, stock-based compensation, accrued research and development costs, pension liabilities, derivative liabilities and redeemable convertible preferred stock liability in the accompanying condensed consolidated financial statements. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.</div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q3 us-gaap Depreciation
Depreciation
387000
us-gaap Operating Lease Payments
OperatingLeasePayments
1885000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12105000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10025000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3513000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1508000
CY2020Q3 algs Accrued Payables Current
AccruedPayablesCurrent
4647000
CY2019Q4 algs Accrued Payables Current
AccruedPayablesCurrent
3113000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4353000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3211000
CY2020Q3 algs Liability With Early Exercised Stock Options Current
LiabilityWithEarlyExercisedStockOptionsCurrent
650000
CY2019Q4 algs Liability With Early Exercised Stock Options Current
LiabilityWithEarlyExercisedStockOptionsCurrent
753000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
132000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
522000
algs Receivable From The Exercise Of Common Stock Options
ReceivableFromTheExerciseOfCommonStockOptions
46000
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21130000
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
556000
CY2019Q3 us-gaap Restricted Cash
RestrictedCash
537000
CY2020Q3 us-gaap Depreciation
Depreciation
708000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-118000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
147000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-38000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-47016000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-85000
CY2020Q3 algs Held To Maturity Securities Total Investments
HeldToMaturitySecuritiesTotalInvestments
15007000
CY2020Q3 algs Held To Maturity Securities Total Investment Fair Value
HeldToMaturitySecuritiesTotalInvestmentFairValue
15063000
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
23109000
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
23109000
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
23241000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-140320000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66197000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2610000
CY2019Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2020Q3 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
15007000
CY2020Q3 us-gaap Held To Maturity Securities Debt Maturities Within One Year Fair Value
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
15063000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
23241000
CY2020Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-11740000
CY2019Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
453000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-10633000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1527000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-4724808
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
The exercise price for incentive stock options is at least 100% of the fair market value on the date of grant for stockholders owning less than 10% of the voting power of all classes of stock, or at least 110% of the fair market value for stockholders owning more than 10% of the voting power of all classes of stock. Options generally expire in 10 years.
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2019Q3 algs Cash Flow From Operations
CashFlowFromOperations
415000
algs Cash Flow From Operations
CashFlowFromOperations
670000
CY2020Q3 algs Percentage Of Principal Amount Of Notes Covered By Warrants
PercentageOfPrincipalAmountOfNotesCoveredByWarrants
0.25
algs Warrants And Rights Outstanding Maturity Period
WarrantsAndRightsOutstandingMaturityPeriod
P10Y
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
278000000
CY2020Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
296000
algs Warrants Issued Closing Date
WarrantsIssuedClosingDate
2018-04-20
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3927803
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
278000000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3927803
CY2020Q3 algs Sale Of Stock Net Consideration Received On Series A Preferred Stock
SaleOfStockNetConsiderationReceivedOnSeriesAPreferredStock
75000000
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
212994964
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
278000000
CY2020Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2019Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-105000
CY2020Q3 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
94000
CY2019Q4 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
47000
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
296000
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
134112
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
132000
CY2020Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
13000
CY2019Q3 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
38000
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-15000
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
85000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33415000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14089000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-73976000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34165000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
637000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4104585
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4104585
algs Payments On Deferred Offering Costs
PaymentsOnDeferredOfferingCosts
1066000
algs Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
1544000
CY2020Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-9.3197
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
638000
CY2020Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
20000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2612000
CY2020Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
79000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2697000
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
78000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17733000
CY2020Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
219000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4593000
CY2020Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
13000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
13140000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
464000
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0934
CY2020Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y11M1D
CY2020Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000
CY2020Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
206000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2444000
CY2020Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
76000
CY2019Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M27D
CY2020Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0316
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2694000
CY2019Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
7000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
0
CY2020Q3 algs Finance Lease Cost
FinanceLeaseCost
21000
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
41000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2678000
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
1000
CY2020Q3 algs Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
6414000
CY2020Q3 algs Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
0
CY2019Q3 algs Finance Lease Cost
FinanceLeaseCost
13000
algs Finance Lease Cost
FinanceLeaseCost
55000
algs Finance Lease Cost
FinanceLeaseCost
29000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y4M9D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M6D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0935
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
568000
us-gaap Operating Lease Cost
OperatingLeaseCost
1397000
us-gaap Operating Lease Cost
OperatingLeaseCost
1774000
CY2020Q3 algs Finance Lease Amortization Of Right Of Use Assets
FinanceLeaseAmortizationOfRightOfUseAssets
19000
CY2019Q3 algs Finance Lease Amortization Of Right Of Use Assets
FinanceLeaseAmortizationOfRightOfUseAssets
11000
algs Finance Lease Amortization Of Right Of Use Assets
FinanceLeaseAmortizationOfRightOfUseAssets
48000
algs Finance Lease Amortization Of Right Of Use Assets
FinanceLeaseAmortizationOfRightOfUseAssets
29000
CY2019Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0318
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
4500000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
744000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
19888000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
24554000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
12859000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y1M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y4M17D
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1016000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
151000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1674000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
604000
CY2020Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2019Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
441198
CY2019 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
577124
CY2020Q3 us-gaap Share Price
SharePrice
650
CY2019Q4 us-gaap Share Price
SharePrice
753
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
algs Preferred Stock Conversion Split
PreferredStockConversionSplit
one-for-one
CY2019 algs Preferred Stock Conversion Split
PreferredStockConversionSplit
one-for-one
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1786000
CY2020Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
38116000
CY2020Q3 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
188000
CY2020Q3 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
0
CY2020Q3 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
38304000
dei Entity Registrant Name
EntityRegistrantName
Aligos Therapeutics, Inc.

Files In Submission

Name View Source Status
0001193125-20-303749-index-headers.html Edgar Link pending
0001193125-20-303749-index.html Edgar Link pending
0001193125-20-303749.txt Edgar Link pending
0001193125-20-303749-xbrl.zip Edgar Link pending
algs-20201031.xml Edgar Link completed
algs-20201031.xsd Edgar Link pending
algs-20201031_cal.xml Edgar Link unprocessable
algs-20201031_def.xml Edgar Link unprocessable
algs-20201031_lab.xml Edgar Link unprocessable
algs-20201031_pre.xml Edgar Link unprocessable
d96959d10q.htm Edgar Link pending
d96959dex311.htm Edgar Link pending
d96959dex312.htm Edgar Link pending
d96959dex321.htm Edgar Link pending
d96959dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending